Home › NDC Lookup › Ingredients › Dasatinib › 70771-1905-03
dasatinib 100 mg Tablet, 30-count — NDC 70771-1905-03 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

dasatinib 100 mg Tablet, 30-count — NDC 70771-1905-3 (Billing 70771-1905-03)

by Zydus Lifesciences Limited · 30 TABLET in 1 BOTTLE

This is a package of 30 tablets of dasatinib 100 mg Tablet from Zydus Lifesciences Limited, marketed since Mar 2025 and currently FDA-listed. It is this product's only package size.

NDC 70771-1905-03
🏷️ FDA NDC (as labeled) 70771-1905-3 billing pads the package segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 70771-1905-3 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
70771 labeler · 1905 product · 3 package
Package marketed since
Mar 3, 2025
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC)
0370710174439, 0370710174163, 0370710174262, 0370710174637 +2 more
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 70771-1905-3
Product NDC 70771-1905
11-digit billing NDC 70771190503
RxCUI 643105, 643107, 643109, 799047, 1045402, 1045406
UNII RBZ1571X5H
UPC 0370710174439, 0370710174163, 0370710174262, 0370710174637 +2 more
Application # ANDA218719
SPL Set ID 4eed6b7b-a09d-4d2e-a345-968dd68323bc
Established class (EPC) Kinase Inhibitor
Mechanism of action Cytochrome P450 3A4 Inhibitors; Protein Kinase Inhibitors
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2025-03-03
Route ORAL
Dosage form TABLET
Substance DASATINIB
TE code (Orange Book) AB · RLD · RS
Quick answers
  • RxCUI (RxNorm): 643105
Why two NDCs? The FDA registers this code as 70771-1905-3 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 70771-1905-03. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Kinase Inhibitor class.

Pharmacologic class Kinase Inhibitor
Drug family (ATC) BCR-ABL tyrosine kinase inhibitors
How it works Protein Kinase Inhibitors, Cytochrome P450 3A4 Inhibitors
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

📖 What it is MedlinePlus · NLM

Dasatinib is used to treat a certain type of chronic myeloid leukemia (CML; a type of cancer of the white blood cells) as a first treatment and in adults who can no longer benefit from other leukemia medications including imatinib (Gleevec®) or in those who cannot take these medications because of side effects. Dasatinib is also used to treat a certain type of chronic CML in children 1 year of age or older. Dasatinib is also used to treat a certain type of acute lymphoblastic leukemia (ALL; a type of cancer of the white blood cells) in adults who can no longer benefit from other leukemia medi...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats certain leukemias that carry the Philadelphia chromosome. These are Ph+ chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL). The exact approval depe...
  • Take it by mouth once a day, with or without food. Swallow the tablet whole. Do not crush, cut or chew it. Follow your prescriber’s directions for your dose.
  • Expect possible low blood counts, fluid retention, diarrhea, headache, rash, fatigue, nausea and shortness of breath. Call your doctor for bleeding, fever, swelling or trouble brea...
  • Usually not. H2 blockers and proton pump inhibitors can lower dasatinib levels, so they should not be used with it. If you need an antacid, take it at least 2 hours before or after...
📖 Read our full Dasatinib guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026 $87.46 $2,623.69 / 30 tablets
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
70771-1905-03 You're viewing this Main listing 30 TABLET in 1 BOTTLE 2025-03-03 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Dasatinib 100 mg 00480-5104-56 Teva 30 tablets $26.457 AB Availability likely —
Dasatinib 100 mg 43598-0603-30 Dr.Reddys 30 tablets $26.457 AB Availability likely —
Dasatinib 100 mg 60505-3631-03 Apotex 30 tablets $26.457 AB Availability likely —
Dasatinib 100 mg 66993-0237-30 Prasco 30 tablets $26.457 AB Availability likely —
Dasatinib 100 mg 68001-0664-04 BluePoint 30 tablets $26.457 AB Availability likely —
Dasatinib 100 mg 70377-0087-11 Biocon 30 tablets $26.457 AB Availability likely —
dasatinib 100 mg 70710-1745-03 Zydus 30 tablets $26.457 AB Availability likely —
Dasatinib 100 mg 70748-0212-06 Lupin 30 tablets $26.457 AB Availability likely —
Dasatinib 100 mg 72603-0926-01 NorthStar 30 tablets $26.457 AB Availability likely —
Sprycel 100 mg 00003-0852-22 E.R. 30 tablets $591.181 AB Availability likely —
Dasatinib 100 mg 46708-0688-30 Alembic 30 tablets — AB FDA listed —
Dasatinib 100 mg 59651-0546-15 Aurobindo 15 tablets — AB FDA listed —
Dasatinib 100 mg 62332-0688-30 Alembic 30 tablets — AB FDA listed —
Phyrago 100 mg 70709-0155-10 Cycle 30 tablets — — FDA listed —
dasatinib 100 mgthis 70771-1905-03 Zydus 30 tablets — AB FDA listed —
Dasatinib 100 mg 73190-0050-30 AvKARE 30 tablets — AB FDA listed —
Dasatinib 100 mg 72205-0323-30 Novadoz 30 tablets — — FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2025
On the market since
Mar 2025
📍
2026
Currently FDA-listed
1 year listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color White
ShapeRound
Imprint1746
Size12 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerZydus Lifesciences Limited
Application holderZYDUS PHARMACEUTICALS USA INC
FDA applicationANDA218719 (ANDA)
Labeler code70771
First marketedMar 2025
Product typeHuman Prescription Drug
Portfolio720 products on file

More NDCs from Zydus Lifesciences Limited labeler code 70771

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 Package Label / Principal Display Panel
📄 Package Label / Principal Display Panel 82 words ▾

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1901-6 Dasatinib Tablets, 20 mg 60 Tablets Rx only Zydus NDC 70771-1902-6 Dasatinib Tablets, 50 mg 60 Tablets Rx only Zydus NDC 70771-1903-6 Dasatinib Tablets, 70 mg 60 Tablets Rx only Zydus NDC 70771-1904-3 Dasatinib Tablets, 80 mg 30 Tablets Rx only Zydus NDC 70771-1905-3 Dasatinib Tablets, 100 mg 30 Tablets Rx only Zydus NDC 70771-1906-3 Dasatinib Tablets, 140 mg 30 Tablets Rx only Zydus 20 mg 50 mg 70 mg 80 mg 100 mg 140 mg

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Dasatinib — the program that covers self-administered drugs. 8 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Dasatinib. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$68.02M
Claims incl. refills
13.6K
Beneficiaries
5.5K
Spend / beneficiary
$12,380.63
Spend / claim
$4,985.28
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Zydus Lifesciences Limited. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Zydus Lifesciences Limited is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 70771-1904-03 · Zydus 70771-1906-03 · Zydus →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.